S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
Log in

West Pharmaceutical Services Stock Forecast, Price & News

-6.45 (-2.15 %)
(As of 01/27/2021 12:00 AM ET)
Today's Range
Now: $293.23
50-Day Range
MA: $287.22
52-Week Range
Now: $293.23
Volume798,219 shs
Average Volume479,619 shs
Market Capitalization$21.68 billion
P/E Ratio77.37
Dividend Yield0.23%
West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, Ireland, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, and washing and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment serves pharmaceutical, diagnostic, and medical device companies. It distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. The company was founded in 1923 and is headquartered in Exton, Pennsylvania.
West Pharmaceutical Services logo


Overall MarketRank

1.92 out of 5 stars

Medical Sector

82nd out of 1,926 stocks

Fabricated Rubber Products, Not Elsewhere Classified Industry

2nd out of 6 stocks

Analyst Opinion: 1.3Community Rank: 2.0Dividend Strength: 3.3Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryHealth Care Supplies
Year FoundedN/A



Sales & Book Value

Annual Sales$1.84 billion
Cash Flow$4.82 per share
Book Value$21.26 per share


Net Income$241.70 million


Market Cap$21.68 billion
Next Earnings Date2/11/2021 (Estimated)
-6.45 (-2.15 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive WST News and Ratings via Email

Sign-up to receive the latest news and ratings for WST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

West Pharmaceutical Services (NYSE:WST) Frequently Asked Questions

How has West Pharmaceutical Services' stock been impacted by COVID-19?

West Pharmaceutical Services' stock was trading at $147.83 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, WST shares have increased by 98.4% and is now trading at $293.23.
View which stocks have been most impacted by COVID-19

Is West Pharmaceutical Services a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" West Pharmaceutical Services stock.
View analyst ratings for West Pharmaceutical Services
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than West Pharmaceutical Services?

Wall Street analysts have given West Pharmaceutical Services a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but West Pharmaceutical Services wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Eric M. Green's approval rating as West Pharmaceutical Services' CEO?

102 employees have rated West Pharmaceutical Services CEO Eric M. Green on Glassdoor.com. Eric M. Green has an approval rating of 74% among West Pharmaceutical Services' employees.

When is West Pharmaceutical Services' next earnings date?

West Pharmaceutical Services is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for West Pharmaceutical Services

How were West Pharmaceutical Services' earnings last quarter?

West Pharmaceutical Services, Inc. (NYSE:WST) issued its earnings results on Thursday, October, 22nd. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. The medical instruments supplier had revenue of $548 million for the quarter, compared to analyst estimates of $510.15 million. West Pharmaceutical Services had a net margin of 14.69% and a trailing twelve-month return on equity of 19.01%. The business's revenue was up 20.2% on a year-over-year basis. During the same quarter last year, the business earned $0.79 earnings per share.
View West Pharmaceutical Services' earnings history

How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?

West Pharmaceutical Services announced a quarterly dividend on Wednesday, December 9th. Shareholders of record on Wednesday, January 20th will be given a dividend of $0.17 per share on Wednesday, February 3rd. This represents a $0.68 dividend on an annualized basis and a yield of 0.23%. The ex-dividend date of this dividend is Tuesday, January 19th.
View West Pharmaceutical Services' dividend history

Is West Pharmaceutical Services a good dividend stock?

West Pharmaceutical Services pays an annual dividend of $0.68 per share and currently has a dividend yield of 0.23%. West Pharmaceutical Services has been increasing its dividend for 25 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of West Pharmaceutical Services is 20.99%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, West Pharmaceutical Services will have a dividend payout ratio of 14.56% next year. This indicates that West Pharmaceutical Services will be able to sustain or increase its dividend.
View West Pharmaceutical Services' dividend history.

What price target have analysts set for WST?

3 Wall Street analysts have issued twelve-month price targets for West Pharmaceutical Services' stock. Their forecasts range from $280.00 to $350.00. On average, they anticipate West Pharmaceutical Services' stock price to reach $310.00 in the next year. This suggests a possible upside of 5.7% from the stock's current price.
View analysts' price targets for West Pharmaceutical Services
or view Wall Street analyst' top-rated stocks.

Who are some of West Pharmaceutical Services' key competitors?

What other stocks do shareholders of West Pharmaceutical Services own?

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include NVIDIA (NVDA), Johnson & Johnson (JNJ), AbbVie (ABBV), The Walt Disney (DIS), The Home Depot (HD), Visa (V), Alibaba Group (BABA), McDonald's (MCD), Netflix (NFLX) and PepsiCo (PEP).

Who are West Pharmaceutical Services' key executives?

West Pharmaceutical Services' management team includes the following people:
  • Mr. Eric M. Green, Pres, CEO & Director (Age 51, Pay $2.28M)
  • Mr. Bernard J. Birkett, Sr. VP & CFO (Age 52, Pay $1.18M)
  • Mr. David A. Montecalvo, Sr. VP and Chief Operations & Supply Chain Officer (Age 56, Pay $801.65k)
  • Mr. Silji Abraham, Chief Digital & Transformation Officer and Sr. VP (Age 49, Pay $796.49k)
  • Mr. George Lloyd Miller, Special Advisor (Age 66, Pay $835.13k)
  • Mr. Chad R. Winters, VP, Chief Accounting Officer, Principal Accounting Officer & Corp. Controller (Age 43)
  • Mr. Eric Resnick, CTO & VP (Age 57)
  • Dr. Quintin J. Lai C.F.A., Ph.D., VP of Corp. Devel., Strategy & Investor Relations (Age 54)
  • Ms. Kimberly Banks MacKay, Sr. VP, Gen. Counsel & Company Sec. (Age 56)
  • Michele Pelkowski, VP of Global Communications

What is West Pharmaceutical Services' stock symbol?

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

Who are West Pharmaceutical Services' major shareholders?

West Pharmaceutical Services' stock is owned by a number of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (0.76%), Congress Asset Management Co. MA (0.56%), Robeco Institutional Asset Management B.V. (0.23%), AMI Asset Management Corp (0.16%), Conestoga Capital Advisors LLC (0.13%) and New York State Teachers Retirement System (0.13%). Company insiders that own West Pharmaceutical Services stock include Annette F Favorite, Daniel Malone, David A Montecalvo, George Lloyd Miller, Patrick J Zenner and Silji Abraham.
View institutional ownership trends for West Pharmaceutical Services

Which institutional investors are selling West Pharmaceutical Services stock?

WST stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Gateway Investment Advisers LLC, Hexavest Inc., Cambridge Trust Co., Summit Creek Advisors LLC, McCollum Christoferson Group LLC, Pacer Advisors Inc., and AMI Asset Management Corp. Company insiders that have sold West Pharmaceutical Services company stock in the last year include Annette F Favorite, David A Montecalvo, George Lloyd Miller, Patrick J Zenner, and Silji Abraham.
View insider buying and selling activity for West Pharmaceutical Services
or view top insider-selling stocks.

Which institutional investors are buying West Pharmaceutical Services stock?

WST stock was bought by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Crossmark Global Holdings Inc., Conestoga Capital Advisors LLC, Peregrine Capital Management LLC, Strs Ohio, Nisa Investment Advisors LLC, Sound Financial Strategies Group LLC, and Janney Montgomery Scott LLC.
View insider buying and selling activity for West Pharmaceutical Services
or or view top insider-buying stocks.

How do I buy shares of West Pharmaceutical Services?

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is West Pharmaceutical Services' stock price today?

One share of WST stock can currently be purchased for approximately $293.23.

How big of a company is West Pharmaceutical Services?

West Pharmaceutical Services has a market capitalization of $21.68 billion and generates $1.84 billion in revenue each year. The medical instruments supplier earns $241.70 million in net income (profit) each year or $3.24 on an earnings per share basis. West Pharmaceutical Services employs 8,200 workers across the globe.

What is West Pharmaceutical Services' official website?

The official website for West Pharmaceutical Services is www.westpharma.com.

How can I contact West Pharmaceutical Services?

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.